pharmaceuticals

Kyntra Bio's entire $700M valuation depends on FG-3246, an antibody-drug conjugate for prostate cancer, mirroring single-asset biotech risks seen globally. The drug faces a 35% Phase 3 failure rate typical of oncology ADCs, with regulatory bars set by competitors Pfizer and AstraZeneca. Clinical setbacks would trigger valuation collapse matching prior biotech wipeouts in US and European markets.

ASX-listed Vectus Biosystems risks delisting after selling its renal anti-fibrotic program to XORTX, with analysts warning proceeds may prove insufficient to sustain operations. The deal follows a global biotech valuation slump, particularly in early-stage kidney disease programs lacking Phase 2 data. Vectus joins 14 Australian life sciences firms that have delisted or entered administration since 2024.

Swedish biotech Novakand Pharma inherits SVF Vaccines' clinical trials across EMA and FDA jurisdictions through reverse takeover, requiring 18-24 months cash reserves under industry standards. Pre-commercial vaccine developers face 40-60% probability of major regulatory setbacks during Phase II-III trials across European and US markets, per EMA data.